FDA Approves OrthoLogic's IND Application for Phase I Dermal Drug
Posted on: Tuesday, 29 January 2008, 09:01 CST
OrthoLogic has announced that the FDA has accepted an investigational new drug application for AZX100 in dermal or hypertrophic scarring. The Phase I human clinical trials will begin during the first quarter of 2008.
The clinical study will be a first-in-man Phase I, randomized, placebo controlled, dose-escalation, single center study in which the safety and tolerability of escalating doses of AZX100 will be evaluated in healthy adult male subjects. A placebo control arm is included in this Phase I study for comparison of injection sites. Approximately 30 adult subjects will be enrolled at an experienced inpatient Phase I study clinic. The primary objective is to evaluate the initial safety and tolerability of AZX100 drug product in healthy adult subjects.
Randolph Steer, president of OrthoLogic, said: "We are now ready to proceed with our Phase I human clinical trial program."
Source: Datamonitor
Related Articles
- Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
- Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
- Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
- Amicus Therapeutics Presents Data From Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
- Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
- Next Generation Nasal Spray Against Influenza: Clinical Phase I Study Started With FLUVACCdelNS1
- Enzo Biochem Reports Long Term Retention of Antisense RNA in Phase I Study of HIV-1 Infected Subjects; Updated Report to International AIDS Conference Calls Results ``Significant''
- TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease
- FoldRx Announces the Initiation of a Phase I Study With First Clinical Candidate
- Altus Pharmaceuticals Announces Completion of Clinical Testing in the Phase I Study of ALTU-238 - a Long-Acting Crystalline Formulation of Human Growth Hormone
 |
 |
User Comments (0)
RSS Feeds